• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Organon & Co.

    4/25/25 4:40:13 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGN alert in real time by email
    DEFA14A 1 defa_14a_fy2024.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material under §240.14a-12

    Organon & Co.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

    img203338807_0.jpg

     

    Your Vote Counts! ORGANON & CO. 2025 Annual Meeting Vote by June 9, 2025 11:59 PM Eastern Daylight Time LOGO ORGANON HERE FOR HER HEALTH ORGANON & CO. 30 HUDSON STREET FLOOR 33 JERSEY CITY, NJ 07302 V71576-P25834 You invested in ORGANON & CO. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 10, 2025. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 27, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually during the Meeting June 10, 2025 9:00 AM Eastern Daylight Time Virtually at: www.virtualshareholdermeeting.com/OGN2025 *Please check the meeting materials for any special requirements for meeting attendance.

     


     

    img203338807_1.jpg

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. Election of Directors Nominees: 1a. Kevin Ali For 1b. Carrie S. Cox For 1c. Robert Essner For 1d. Alan Ezekowitz, M.D., Ph. D. For 1e. Helene Gayle, M.D. For 1f. Rochelle B. Lazarus For 1g. Deborah Leone For 1h. Philip Ozuah, M.D., Ph. D. For 1i. Cynthia M. Patton For 1j. Grace Puma For 1k. Shalini Sharp For 2. Approve, on a non-binding advisory basis, the compensation of Organon’s Named Executive Officers. For 3. Approval of an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan. For 4. Ratify the appointment of PricewaterhouseCoopers LLP as Organon’s independent registered public accounting firm for 2025. For 5. Shareholder proposal requesting adoption of a director election resignation guideline. Against NOTE: The proxies are authorized to vote in their discretion upon such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V71577-P25834

     


    Get the next $OGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OGN

    DatePrice TargetRatingAnalyst
    5/2/2025Outperform → In-line
    Evercore ISI
    9/6/2024$18.00 → $20.00Neutral → Underweight
    JP Morgan
    11/3/2023$33.00 → $16.00Buy → Neutral
    Goldman
    9/21/2023$28.00Overweight
    Barclays
    3/16/2023$33.00Outperform
    Raymond James
    10/14/2022$27.00 → $25.00Neutral → Underperform
    BofA Securities
    9/6/2022$37.00 → $34.00Neutral → Overweight
    Piper Sandler
    8/5/2022$40.00 → $37.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $OGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Organon Reports Results for the First Quarter Ended March 31, 2025

      Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs in 2025 Vtama on track to achieve $150 million revenue target for full year 2025; double-digit growth in Nexplanon in the first quarter Company resets capital allocation priorities to accelerate progress towards deleveraging; new annual regular dividend rate of $0.08 per share First quarter 2025 revenue of $1.513 billion, down 7% as-reported and down 4% at constant currency, consistent with company's expectation

      5/1/25 7:00:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

      Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

      4/15/25 5:00:00 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

      Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or milestones due to the level of uncertainty and ability to forecast the timing of such achievements. As such, these milestones, as well as any future IPR&D and milestones are not contemplated in the company's financial guidance provided on Feb

      4/15/25 7:31:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/15/25 4:09:09 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Human Resources Officer Falcione Aaron bought $48,235 worth of shares (5,500 units at $8.77), increasing direct ownership by 10% to 62,974 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:13:47 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gen. Counsel & Corp. Secy. Weaver Kirke bought $74,054 worth of shares (8,045 units at $9.21), increasing direct ownership by 18% to 52,489 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:12:22 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Financials

    Live finance-specific insights

    See more
    • Organon Reports Results for the First Quarter Ended March 31, 2025

      Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs in 2025 Vtama on track to achieve $150 million revenue target for full year 2025; double-digit growth in Nexplanon in the first quarter Company resets capital allocation priorities to accelerate progress towards deleveraging; new annual regular dividend rate of $0.08 per share First quarter 2025 revenue of $1.513 billion, down 7% as-reported and down 4% at constant currency, consistent with company's expectation

      5/1/25 7:00:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

      Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or milestones due to the level of uncertainty and ability to forecast the timing of such achievements. As such, these milestones, as well as any future IPR&D and milestones are not contemplated in the company's financial guidance provided on Feb

      4/15/25 7:31:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

      Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and

      4/1/25 7:30:00 AM ET
      $BIIB
      $OGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $OGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

      Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

      4/15/25 5:00:00 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

      Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel

      3/10/25 12:01:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

      Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women's health. KIRKLAND, QC, Oct. 8, 2024 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, today announced updates to its Canadian leadership team with an appointment and promotion. Effective September 1, 2024, Jeffrey Malawsk

      10/8/24 8:01:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/15/25 4:09:09 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Human Resources Officer Falcione Aaron bought $48,235 worth of shares (5,500 units at $8.77), increasing direct ownership by 10% to 62,974 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:13:47 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gen. Counsel & Corp. Secy. Weaver Kirke bought $74,054 worth of shares (8,045 units at $9.21), increasing direct ownership by 18% to 52,489 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:12:22 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Organon downgraded by Evercore ISI

      Evercore ISI downgraded Organon from Outperform to In-line

      5/2/25 8:13:50 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon downgraded by JP Morgan with a new price target

      JP Morgan downgraded Organon from Neutral to Underweight and set a new price target of $20.00 from $18.00 previously

      9/6/24 7:47:49 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon downgraded by Goldman with a new price target

      Goldman downgraded Organon from Buy to Neutral and set a new price target of $16.00 from $33.00 previously

      11/3/23 7:22:32 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Organon & Co.

      10-Q - Organon & Co. (0001821825) (Filer)

      5/2/25 8:42:12 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon & Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Organon & Co. (0001821825) (Filer)

      5/1/25 7:12:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Organon & Co.

      DEFA14A - Organon & Co. (0001821825) (Filer)

      4/25/25 4:40:13 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Organon & Co. (Amendment)

      SC 13G/A - Organon & Co. (0001821825) (Subject)

      2/13/24 5:12:22 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Organon & Co. (Amendment)

      SC 13G/A - Organon & Co. (0001821825) (Subject)

      2/5/24 3:47:19 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Organon & Co. (Amendment)

      SC 13G/A - Organon & Co. (0001821825) (Subject)

      1/25/24 12:23:52 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care